ACOG Practice Pearls Verified Exam Questions and Answers Latest
update 2026/2027
Question:
1. Most common hereditary cancer syndromes related to women's cancer (793)
Answer:
-Lynch
-Li-Fraumeni
-Cowden Syndrome
-Peutz-Jeghers syndrome
-hereditry dittuse gastric cancer
L-LF-C-PJ-G
Question:
2. What is included in hereditary cancer risk assessment? (793)
Answer:
- Family hx
- Personal hx
(include pathology, imaging reports, evaluation of other risk factors for cancer)
Question:
3. Next step if hereditary cancer risk assessment if positive? (793)
Answer:
Referral
- specialist in cancer genetics
- HCP with expertise in genetics
- expanded hx taking, risk assessment, counseling, education, enhanced
genetic testing, tailored cancer screening, risk reduction.
Question:
4. Benefits of multigene sequencing technology (793)
Answer:
- Increases likelihood of finding variants of unknown significance. Allows for
testing for pathogenic and likely pathogenic variants of unknown significance.
- Multigene testing is recommended by ACOG.
,Question:
5. Which germline mutations account for most cases of hereditary breast and ovarian cancer
syndrome? (182)
Answer:
BRCA1 and BRCA2
Question:
6.
Who should receive genetic counseling? (182)
Answer:
- All patients with ovarian epithelial cancer including fallopian and primary
peritoneal cancer.
- individuals with personal or family history of breast/ovarian cancer.
Question:
7. Who should be offered prophylactic bilateral mastectomy or bilateral salpingo-oopherectomy?
(182)
Answer:
- Women with BRCA mutations.
- Other actionable deleterious mutations that predispose people to breast
or ovarian cancer.
Question:
8. What age should BRCA 1 carriers be recommended prophylactic bilateral salpingo-oopherectomy?
(182)
Answer:
35-40 years old Earlier than BRCA 2. Higher lifetime r/o ovarian cancer
Question:
9. What age should BRCA 2 carriers be recommended prophylactic bilateral salpingo-oopherectomy?
(182)
Answer:
40-45 years old Later onset of ovarian cancer likely in BRCA 2 vs 1.
Question:
10. What are the 2 main genetic testing options for breast and ovarian cancer syndrome? (182)
Answer:
1. BRCA mutation testing
2. Multigene panel testing (includes BRCA)
- use when suspicious of inherited cancer syndrome.
, Question:
11. T/F: TVUS and serum CA 125 levels should
be used for routine ovarian cancer screening in those with BRCA mutations or with personal/family
history of ovarian cancer. (182)
Answer:
FALSE - this is NOT recommended. TVUS and CA125 levels are only reasonable in short-term
surveillance in women at high risk of ovarian cancer at 30-35 years of age until they choose to pursue
a bilateral salpingo-oopherectomy.
Question:
12. Only proven intervention to reduce ovarian cancer-specific mortality (182)
Answer:
Risk-reducing bilateral salpingo-oopherectomy
Question:
13. What is recommended for breast cancer surveillance in
Answer:
- Clinical breast exam q6-12 months
- Annual radiographic screening (MRI w/ contrast)
Question:
25. -29 year-olds with
known BRCA? (182)
Answer:
Question:
14. For women with known BRCA mutations over 30, what breast cancer surveillance is
recommended? (182)
Answer:
- Annual MRI with contrast
- Annual mammography
(Alternate q 6 months)
update 2026/2027
Question:
1. Most common hereditary cancer syndromes related to women's cancer (793)
Answer:
-Lynch
-Li-Fraumeni
-Cowden Syndrome
-Peutz-Jeghers syndrome
-hereditry dittuse gastric cancer
L-LF-C-PJ-G
Question:
2. What is included in hereditary cancer risk assessment? (793)
Answer:
- Family hx
- Personal hx
(include pathology, imaging reports, evaluation of other risk factors for cancer)
Question:
3. Next step if hereditary cancer risk assessment if positive? (793)
Answer:
Referral
- specialist in cancer genetics
- HCP with expertise in genetics
- expanded hx taking, risk assessment, counseling, education, enhanced
genetic testing, tailored cancer screening, risk reduction.
Question:
4. Benefits of multigene sequencing technology (793)
Answer:
- Increases likelihood of finding variants of unknown significance. Allows for
testing for pathogenic and likely pathogenic variants of unknown significance.
- Multigene testing is recommended by ACOG.
,Question:
5. Which germline mutations account for most cases of hereditary breast and ovarian cancer
syndrome? (182)
Answer:
BRCA1 and BRCA2
Question:
6.
Who should receive genetic counseling? (182)
Answer:
- All patients with ovarian epithelial cancer including fallopian and primary
peritoneal cancer.
- individuals with personal or family history of breast/ovarian cancer.
Question:
7. Who should be offered prophylactic bilateral mastectomy or bilateral salpingo-oopherectomy?
(182)
Answer:
- Women with BRCA mutations.
- Other actionable deleterious mutations that predispose people to breast
or ovarian cancer.
Question:
8. What age should BRCA 1 carriers be recommended prophylactic bilateral salpingo-oopherectomy?
(182)
Answer:
35-40 years old Earlier than BRCA 2. Higher lifetime r/o ovarian cancer
Question:
9. What age should BRCA 2 carriers be recommended prophylactic bilateral salpingo-oopherectomy?
(182)
Answer:
40-45 years old Later onset of ovarian cancer likely in BRCA 2 vs 1.
Question:
10. What are the 2 main genetic testing options for breast and ovarian cancer syndrome? (182)
Answer:
1. BRCA mutation testing
2. Multigene panel testing (includes BRCA)
- use when suspicious of inherited cancer syndrome.
, Question:
11. T/F: TVUS and serum CA 125 levels should
be used for routine ovarian cancer screening in those with BRCA mutations or with personal/family
history of ovarian cancer. (182)
Answer:
FALSE - this is NOT recommended. TVUS and CA125 levels are only reasonable in short-term
surveillance in women at high risk of ovarian cancer at 30-35 years of age until they choose to pursue
a bilateral salpingo-oopherectomy.
Question:
12. Only proven intervention to reduce ovarian cancer-specific mortality (182)
Answer:
Risk-reducing bilateral salpingo-oopherectomy
Question:
13. What is recommended for breast cancer surveillance in
Answer:
- Clinical breast exam q6-12 months
- Annual radiographic screening (MRI w/ contrast)
Question:
25. -29 year-olds with
known BRCA? (182)
Answer:
Question:
14. For women with known BRCA mutations over 30, what breast cancer surveillance is
recommended? (182)
Answer:
- Annual MRI with contrast
- Annual mammography
(Alternate q 6 months)
